Table 1
Nucleotide change, haplotype and genotype frequencies of CYP2C8 in Serbian epileptic pediatric patients on carbamazepine treatment.
| Observed Frequency | 95% CI | |
|---|---|---|
| Nucleotide change: 416G>A 475delA | 0.100 (8/80) 0.000 (0/80) | 0.050, 0.188 0.000, 0.056 |
| Haplotype: CYP2C8*1A CYP2C8*3 CYP2C8*5 | 0.900 (72/80) 0.100 (8/80) 0.000 (0/80) | 0.812, 0.950 0.050, 0.188 0.000, 0.056 |
| Genotype: CYP2C8*1A/1A CYP2C8*1A/*3 CYP2C8*3/*3 | 0.825 (33/40) 0.150 (6/40) 0.025 (1/40) | 0.676, 0.861 0.068, 0.245 0.000, 0.109 |
95% CI: 95% confidence interval.
Comparison between CYP2C8 genotype groups in terms of obtained dose-normalized serum concentration of carbamazepine after dose adjustment.
Correlation between weight-adjusted daily dose of carbamazepine and carbamazepine serum concentrations according to the CYP2C8*3 genotype group.
Table 2
The final model parameter estimates.
| Parameters | NONMEM | Bootstrap Analysis | ||
|---|---|---|---|---|
| Estimate | 95% CIaa | Estimate | 95% CIbb | |
| Clearance (L/h) | 0.215 | 0.176-0.254 | 0.207 | 0.189-0.225 |
| Sex | 0.0696 | 0.0545-0.0847 | 0.0698 | 0.0527-0.869 |
| Daily dose of carbamazepine (mg/L) | 0.000183 | 0.000079-0.000287 | 0.000194 | 0.000141-0.000247 |
| Inter-individual variance of CL | 0.0626 | 0.0371-0.0881 | 0.0669 | 0.058-0.0758 |
| Residual variance (exponential) | 0.0249 | 0.018-0.318 | 0.0262 | 0.023-0.0294 |
NONMEM: nonlinear mixed effect model.